Bioventus Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
BVS$11.02+3.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| 2024 | 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $41,582 | $36,964 |
| Accounts receivable, net | 127,393 | 122,789 |
| Inventory | 92,475 | 91,333 |
| Prepaid and other current assets | 14,160 | 16,913 |
| Total current assets | 275,610 | 267,999 |
| Property and equipment, net | 27,012 | 36,605 |
| Goodwill | 7,462 | 7,462 |
| Intangible assets, net | 404,729 | 482,350 |
| Operating lease assets | 6,506 | 13,353 |
| Deferred tax assets | 4,745 | — |
| Investment and other assets | 1,892 | 3,141 |
| Total assets | $727,956 | $810,910 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $23,690 | $23,038 |
| Accrued liabilities | 135,879 | 119,795 |
| Current portion of long-term debt | 27,339 | 27,848 |
| Current portion of contingent consideration | 19,573 | — |
| Other current liabilities | 3,917 | 4,816 |
| Total current liabilities | 210,398 | 175,497 |
| Long-term debt, less current portion | 308,288 | 366,998 |
| Deferred income tax liabilities | 564 | 1,213 |
| Contingent consideration | — | 18,150 |
| Other long-term liabilities | 23,102 | 27,934 |
| Total liabilities | 542,352 | 589,792 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ Equity: | ||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued | ||
| Class A common stock, $0.001 par value, 250,000,000 shares authorized as of December 31, 2024 and December 31, 2023, 65,758,341 and 63,267,436 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | 66 | 63 |
| Class B common stock, $0.001 par value, 50,000,000 shares authorized, 15,786,737 shares issued and outstanding as of December 31, 2024 and December 31, 2023 | 16 | 16 |
| Additional paid-in capital | 505,509 | 494,254 |
| Accumulated deficit | (355,078) | (321,536) |
| Accumulated other comprehensive (loss) income | (2,573) | 794 |
| Total stockholders’ equity attributable to Bioventus Inc. | 147,940 | 173,591 |
| Noncontrolling interest | 37,664 | 47,527 |
| Total stockholders’ equity | 185,604 | 221,118 |
| Total liabilities and stockholders’ equity | $727,956 | $810,910 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.